ABOUT CANCER
EARLY SCREENING

01

EMPOWERING MORE
FAMILIES, EARLIER

Genetron aims to radically improve the accessibility, affordability, and accuracy of early detection solutions for you and your family. Expanding from single cancer types to multiple cancer types, R&D breakthroughs and product commercialization must not only meet clinical needs, but also elevate service standards—only then can we reduce the mortality rate of cancer and foster lasting, generational impact.

02

LIVER CANCER, THE FIRST BREAKTHROUGH

In March 2019, Genetron—in collaboration with the National Cancer Center (PRC) and the Cancer Hospital of the China Academy of Medical Sciences—published the research breakthroughs for a prospective cohort for early screening of liver cancer in the Proceedings of the National Academy of Sciences (PNAS).

In August 2020, the Ministry of Science and Technology (PRC) launched a national R&D project for early cancer screening, selecting Genetron Health to participate in developing key technologies for the early detection of multiple cancer types

TECHNOLOGY BREAKTHROUGH

88%

SENSITIVITY

93%

SPECIFICITY

FINDING EARLY LIVER CANCER
AT THE ASYMPTOMATIC STAGE,
WHEN IT CAN BE CURED

Owing to its superior clinical performance over the current medical standard (i.e. Type-B ultrasound & AFP protein detection), Genetron Health's liver cancer early screening technology HCCscreenTM received the "Breakthrough Device Designation" from the US FDA.1 1 Based on results from the prospective cohort study using Genetron's high-throughput sequencing (NGS) liquid biopsy.

SERVICE REACH

Using HCCscreen™️, Genetron Health offers product distribution and service coverage across three major commercial channels.

...
PUBLIC HEALTH PROGRAM

A “Liver Cancer Early SCREENING Comprehensive Prevention Program,” launched in collaboration with the National Cancer Center and Wuxi Municipality Huishan District Government.

...
CLINICAL INSTITUTIONS

An exclusive strategic cooperation with CTTQ Pharma to jointly service the hospital market, providing precision oncology solutions to high-risk clinical patients with liver disease.

...
HIGH-RISK POPULATION

An exclusive strategic cooperation with iKang Group to provide early screening products for the general population, covering over 150 locations across all of China.

CASE STUDIES
EARLY STAGE CASE STUDY - MR.LIU
WUXI CASE STUDY – MR. LI

PARTNERS